Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Iterum Therapeutics plc - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ITRM
Nasdaq
2830
www.iterumtx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Iterum Therapeutics plc
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
- Jan 31st, 2025 1:00 pm
Iterum Therapeutics Regains Full Nasdaq Compliance
- Nov 21st, 2024 1:30 pm
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...
- Nov 15th, 2024 7:10 am
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
- Nov 14th, 2024 12:00 pm
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
- Nov 11th, 2024 1:00 pm
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships
- Oct 28th, 2024 2:19 pm
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment
- Oct 28th, 2024 11:49 am
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
- Oct 28th, 2024 9:00 am
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
- Oct 25th, 2024 3:03 pm
Iterum Therapeutics to Present Data at IDWeek 2024
- Oct 10th, 2024 12:30 pm
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
- Oct 9th, 2024 9:00 pm
Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts
- Sep 24th, 2024 2:33 pm
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
- Sep 11th, 2024 4:04 pm
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
- Sep 10th, 2024 11:00 am
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
- Sep 6th, 2024 8:30 pm
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable?
- Aug 16th, 2024 11:18 am
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
- Aug 14th, 2024 11:00 am
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- Aug 7th, 2024 8:30 pm
Iterum Therapeutics Announces Expiration and Results of Rights Offering
- Aug 6th, 2024 9:30 pm
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
- Aug 2nd, 2024 12:00 pm
Scroll